Trial Profile

A Phase I, Open-label, Randomized, Active-Controlled Study in Adults to Characterize the Safety and Immunogenicity of AZD9838 and AZD6563 Vaccine (ARTEMIS-C)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD 9838 (Primary) ; RNA vaccines
Indications COVID 2019 infections
Focus Adverse reactions; Pharmacodynamics
Acronyms ARTEMIS-C
Sponsors AstraZeneca

Most Recent Events

07 May 2024 Planned End Date changed from 11 Apr 2025 to 10 Apr 2025.
07 May 2024 Status changed from recruiting to active, no longer recruiting.
13 Mar 2024 Planned number of patients changed from 90 to 240.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com